Axsome Therapeutics, Inc.
AXSM
$118.51
$1.371.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.26% | 20.69% | -15.96% | 18.58% | -16.07% |
| Total Depreciation and Amortization | 5.30% | 2.89% | 0.58% | 3.41% | 8.85% |
| Total Amortization of Deferred Charges | -52.47% | -5.79% | 5.36% | 4.84% | 3.55% |
| Total Other Non-Cash Items | 16.81% | -29.41% | -13.30% | 61.09% | 23.24% |
| Change in Net Operating Assets | -41.21% | -179.30% | 154.61% | -78.03% | 436.14% |
| Cash from Operations | 25.25% | -65.54% | -40.64% | 38.12% | 43.68% |
| Capital Expenditure | 96.15% | -1,026.67% | 66.67% | -73.08% | 46.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 96.15% | -1,026.67% | 66.67% | -73.08% | 46.94% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -47,906.48% | -21.52% | -6.11% | -67.20% | -14.11% |
| Issuance of Common Stock | 20.74% | 108.83% | -47.39% | 85.45% | 619.91% |
| Repurchase of Common Stock | 79.52% | -713.51% | -12.68% | 64.38% | 17.92% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -137.42% | -8.86% | -11.72% | -4.21% | -10.80% |
| Cash from Financing | 18.01% | 105.49% | -53.15% | 111.47% | 1,311.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 114.58% | -20.48% | -202.60% | 174.02% | 71.17% |